Citation Impact 2023
Journal Impact Factor: 4.4
5-year Journal Impact Factor: 4.9
Source Normalized Impact per Paper (SNIP): 1.294
SCImago Journal Rank (SJR): 1.518
Speed 2023
Submission to first editorial decision (median days): 9
Submission to acceptance (median days): 111
Usage 2023
Downloads: 3,331,819
Altmetric mentions: 1,885
Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis
Angiogenesis is an important factor in the development of osteoarthritis (OA). We investigated the efficacy of bevacizumab, an antibody against vascular endothelial growth factor and an inhibitor of angiogenes...